Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Allergan

Status and phase: Completed; Phase 3

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: Brimonidine ophthalmic solution 0.2%; Drug: Brimonidine ophthalmic solution 0.1%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00652483

190342-021

Details and patient eligibility

About

This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension

Enrollment: 433 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ocular hypertension or glaucoma in both eyes

Exclusion criteria

• Uncontrolled systemic disease
• Known allergy or sensitivity to brimonidine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

433 participants in 2 patient groups

1

Experimental group

Description:

Brimonidine ophthalmic solution 0.1%

Treatment:

Drug: Brimonidine ophthalmic solution 0.1%

2

Active Comparator group

Description:

Brimonidine ophthalmic solution 0.2%

Treatment:

Drug: Brimonidine ophthalmic solution 0.2%